[{"id":"2fe5c637-4e3d-4c63-9f81-6c13c0cc1278","acronym":"","url":"https://clinicaltrials.gov/study/NCT00910728","created_at":"2021-01-18T03:31:08.657Z","updated_at":"2024-07-02T16:37:23.143Z","phase":"Phase 1","brief_title":"Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases","source_id_and_acronym":"NCT00910728","lead_sponsor":"AstraZeneca","biomarkers":" JAK2","pipe":" | ","alterations":" JAK2 mutation","tags":["JAK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD1480"],"overall_status":"Completed","enrollment":" Enrollment 65","initiation":"Initiation: 05/01/2009","start_date":" 05/01/2009","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-04-24"}]